Uriach acquires the HuPaVir brand to complete its immune system product portfolio

October 17, 2022by admin

The Catalan company Uriach closes with NTD Labs the acquisition of its brand HuPaVir to complete its portfolio of products on the immune system. The new treatment is incorporated into the Uriach Medical line to integrate the category of products aimed at preventing the spread of HPV (Human Papilloma Virus). Thus, with HuPaVir (in sachets) and Colpofix (vaginal spray) all stages of infection are covered.


The price of the transaction is unknown for "legal and confidentiality reasons", as this medium has learned. The agreement signed with NTD Labs includes the license to use the brand and exclusive marketing rights for Spain, among other strategic countries for the group. “The presence of Colpofix in more than twenty countries will help the integration of Hupavir in these same countries, in order to offer the most complete option in the HPV market”, explains the Catalan laboratory through a statement.

The new brand arrives to reinforce its Uriach Medical line (Laborest, in Italy), launched in Spain in 2017, with the aim of complementing its Colpofix product in the category of gynecological products. From the company they point out that "they do not intend it to be a star product", since their main strategic bets continue to be their Fisiocrem and Aquilea brands and the products that make up the Uriach Medical line.

HuPaVir is a food supplement that contains the patented ingredient Ditriamino, as well as vitamin A, niacin, folic acid and zinc, to help strengthen the immune system and promote natural control of infection. It is positioned among the leading players in the Spanish HPV market with a 20% market share (1 million euros of sales).

The company closed 2021 with a turnover of 235 million euros. The operation represents a further step towards the implementation of the 2022-2025 Strategic Plan, which includes levers for organic and inorganic growth, with the aim of positioning itself as the European leader in the Natural Consumer Healthcare segment. In this way, its objective for 2025 would be to double the results until to reach 500 million sales and 80 million Ebitda (gross operating result).


Posted by The Economist


This site uses cookies for you to have the best user experience. If you continue to browse you are giving your consent to the acceptance of the aforementioned cookies and acceptance of our Cookies policy, Click the link for more information.plugin cookies

Notice of cookies